Oral and Palmitate Paliperidone Long-Acting Injectable Formulations’ Use in Schizophrenia Spectrum Disorders: A Retrospective Cohort Study from the First Episode Psychosis Intervention Program (CRUPEP)

Autor: O. Mentxaka, M Recio-Barbero, L F Callado, J Cabezas-Garduño, J I Eguíluz, Rafael Segarra, M. Sáenz-Herrero
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
functional recovery
medicine.medical_treatment
Administration
Oral
Regular Research Articles
Outcome Assessment
Health Care
Pharmacology (medical)
relapse
First episode
Positive and Negative Syndrome Scale
AcademicSubjects/SCI01870
schizophrenia spectrum disorders
Middle Aged
Psychiatry and Mental health
Tolerability
Female
paliperidone
metaanalysis
medicine.drug
Antipsychotic Agents
Adult
medicine.medical_specialty
First episode psychosis
AcademicSubjects/MED00415
recent-onset
Injections
Young Adult
remission
nonaffective psychosis
Internal medicine
first episode psychosis
Paliperidone Palmitate
medicine
Humans
Paliperidone
Antipsychotic
Retrospective Studies
Pharmacology
Risperidone
risperidone
business.industry
Retrospective cohort study
long-acting injectable antipsychotics
recent-onset psychosis
antipsychotics
predictors
Psychotic Disorders
Delayed-Action Preparations
Clinical Global Impression
Schizophrenia
business
discontinuation
Zdroj: International Journal of Neuropsychopharmacology
Addi. Archivo Digital para la Docencia y la Investigación
instname
ISSN: 1469-5111
1461-1457
Popis: Background Long-acting injectable antipsychotics (LAIs) may be a suitable therapeutic option for those patients in earlier stages of psychosis to avoid relapses and disease progression. Despite that, there is a lack of evidence in the literature regarding the use of LAIs in this profile of patients. Methods This is a retrospective cohort analysis to assess the efficacy, tolerability, and pattern of use of palmitate paliperidone long-acting injectable (PPLAI) formulations (1- and 3-month doses) compared to oral paliperidone/risperidone in patients with a nonaffective first episode of psychosis (FEP) over 12 months of follow-up. Relevant sociodemographic and clinical information were assessed, as well as main clinical scales: Positive and Negative Syndrome Scale, Personal and Social Performance Scale, and Clinical Global Impression Scale Improvement and Severity measures. Results The study included 48 patients, 16 per arm, who were aged 20–50 years and had an FEP. Significant improvements were registered for all treatment groups. Despite that, patients receiving PPLAI 1- and 3-month formulations obtained greater improvements than those in the oral group in the main domains assessed (P < .001). We found no statistically significant differences in hospitalizations between groups. Side effects were presented in 24% of patients. A trend towards reducing antipsychotic doses was observed in 43.8% of patients to achieve the minimum effective dose and avoid the occurrence of side effects. Conclusions To our knowledge, this is the first study assessing the use of palmitate paliperidone long-acting formulations versus oral risperidone or paliperidone in FEP. Treatment with PPLAI formulations seems to be an effective therapeutic choice at earlier stages of the disease.
Databáze: OpenAIRE
Externí odkaz: